- Home
- GTBP
GTBP
GT Biopharma Inc.
as 11-15-2024 3:35pm EST
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
| Founded: | 1965 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 6.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 28.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $10.66 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GT Biopharma Inc. News
GTBP Breaking Stock News: Dive into GTBP Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
GT Biopharma Reports Third Quarter 2024 Financial Results
GlobeNewswire
2 months ago
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GlobeNewswire
2 months ago
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline and Broad Indication Potential on October 10, 2024
GlobeNewswire
3 months ago
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5 months ago
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
Simply Wall St.
5 months ago
With 58% ownership, Berliner Effektengesellschaft AG (FRA:BFV) insiders have a lot at stake
Motley Fool
5 months ago
Better AI Stock: Palantir vs. Snowflake
Motley Fool
5 months ago
Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?
Compare GTBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GTBP GT Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.